Experimental and Molecular Medicine (Jun 2024)

RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma

  • Shanjia Ke,
  • Shounan Lu,
  • Yanan Xu,
  • Miaoyu Bai,
  • Hongjun Yu,
  • Bing Yin,
  • Chaoqun Wang,
  • Zhigang Feng,
  • Zihao Li,
  • Jingjing Huang,
  • Xinglong Li,
  • Baolin Qian,
  • Yongliang Hua,
  • Yao Fu,
  • Bei Sun,
  • Yaohua Wu,
  • Yong Ma

DOI
https://doi.org/10.1038/s12276-024-01244-9
Journal volume & issue
Vol. 56, no. 6
pp. 1412 – 1425

Abstract

Read online

Abstract Hepatocellular carcinoma (HCC) is one of the most common fatal cancers worldwide, and the identification of novel treatment targets and prognostic biomarkers is urgently needed because of its unsatisfactory prognosis. Regulator of G-protein signaling 19 (RGS19) is a multifunctional protein that regulates the progression of various cancers. However, the specific function of RGS19 in HCC remains unclear. The expression of RGS19 was determined in clinical HCC samples. Functional and molecular biology experiments involving RGS19 were performed to explore the potential mechanisms of RGS19 in HCC. The results showed that the expression of RGS19 is upregulated in HCC tissues and is significantly associated with poor prognosis in HCC patients. RGS19 promotes the proliferation and metastasis of HCC cells in vitro and in vivo. Mechanistically, RGS19, via its RGS domain, stabilizes the MYH9 protein by directly inhibiting the interaction of MYH9 with STUB1, which has been identified as an E3 ligase of MYH9. Moreover, RGS19 activates β-catenin/c-Myc signaling via MYH9, and RGS19 is also a transcriptional target gene of c-Myc. A positive feedback loop formed by RGS19, MYH9, and the β-catenin/c-Myc axis was found in HCC. In conclusion, our research revealed that competition between RGS19 and STUB1 is a critical mechanism of MYH9 regulation and that the RGS19/MYH9/β-catenin/c-Myc feedback loop may represent a promising strategy for HCC therapy.